

[Help](#)
[Logout](#)
[Main Menu](#) | [Search Form](#) | [Result Set](#) | [Show S Numbers](#) | [Edit S Numbers](#)
[First Hit](#)
[Previous Document](#)
[Next Document](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	------------------------	---------------------

Document Number 4

Entry 4 of 4

File: DWPI

Jan 20, 1994

DERWENT-ACC-NO: 1994-035056

DERWENT-WEEK: 199404

COPYRIGHT 2000 DERWENT INFORMATION LTD

TITLE: New nucleic acid fragment encoding gene products - can be used for genetic analysis and mapping

INVENTOR: GROSS, J; HADFIELD, K M ; HOWELLS, D ; KELLY, M ; SHAW, D ; SIBSON, D R ; STARKEY, M

PATENT-ASSIGNEE: MEDICAL RES COUNCIL[MEDIN]

PRIORITY-DATA:

APPL-NO

APPL-DATE

1992GB-0014857

July 13, 1992

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9401548 A2	January 20, 1994	E	612	C12N015/11
AU 9345121 A	January 31, 1994	N/A	000	C12N015/11
EP 587279 A1	March 16, 1994	E	727	N/A
WO 9401548 A3	March 31, 1994	N/A	000	C12N015/11

DESIGNATED-STATES: AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN AT BE CH DE DK ES FR GB GR IE IT LU MC NL OA PT SE AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

CITED-DOCUMENTS: 5.Jnl.Ref; WO 9302214 ; No-SR.Pub

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	APPL-DESCRIPTOR
WO 9401548A2	July 13, 1993	1993WO-GB01467	N/A
AU 9345121A	July 13, 1993	1993AU-0045121	N/A
AU 9345121A	N/A	WO 9401548	Based on
EP 587279A1	July 13, 1993	1993EP-0305451	N/A
WO 9401548A3	July 13, 1993	1993WO-GB01467	N/A

INT-CL (IPC): C07K 15/28; C12N 15/11; C12N 15/62; C12P 21/08; C12Q 1/68

ABSTRACTED-PUB-NO: WO 9401548A

BASIC-ABSTRACT:

The following are claimed: (1) a nucleic acid (NA) fragment (I) encoding a gene product or a portion of it comprising: (a) a sequence selected from one of 1193 sequences (which are given in full in the specification); (b) an allelic variation of a sequence as in (a); or (c) a sequence complementary to (a) or (b); (2) a NA sequence (II) as set out in any one of the 1193

specified sequences, or a complement or allelic variation of it; (3) a DNA construct, comprising (I) or (II) together with a control or regulatory sequence; (4) the use of (I) or (II) to produce a gene (III); (5) a DNA fragment (DF) comprising (III), obtd. as in (4); (6) an expression vector (IV) comprising (I), (II), a DNA construct as in (3), or DF, positioned such that NA sequence which encodes the polypeptide corresponding to (I). (II) or DF is in operable reading frame with a control or regulatory sequence; (7) host cells (V) which incorporate as a heterologous part of their expressible genetic information (I), (II) or DF; (8) an antibody (Ab) directed against a polypeptide (PP) obtd. by cultivating (V); and (9) a novel gene, or its portion encoded by (I), (II) or by the genes comprised in a DF as in (5).

USE/ADVANTAGE - The Abs can be used for localising in situ, or quantifying in samples through, e.g. ELISA or RIA assays, peptides against which they were raised. These uses are particularly beneficial when the results of the assays can be correlated to a disease condition, e.g. cancer. For example tumour markers may be found and used to target therapeutic agents. The Abs can also be used to detect or monitor markers of undifferentiated growth, infection, cardiovascular or immune disease or a therapeutic response. The sequences or fragments can also be used for genetic analysis and mapping, e.g., to diagnose the likelihood that a given individual is predisposed towards a given genetic disease. Abs can be produced against the protein of a genetic disease with sufficient discriminating power to discriminate between diseased and non-diseased states. This would be useful for reducing the dependence of such tests on NA-based screens. Such Abs also have the advantage of allowing detection of faulty expression of the protein, for e.g. levels of expression which may be important for development of the disease in slow onset conditions.

ABSTRACTED-PUB-NO: WO 9401548A
EQUIVALENT-ABSTRACTS:

CHOSEN-DRAWING: Dwg.0/0

DERWENT-CLASS: B04 D16

CPI-CODES: B04-E01; B04-E02E; B04-E08; B04-F10; B04-G01; B12-K04; D05-H09; D05-H11; D05-H12A; D05-H12E; D05-H14;

Main Menu	Search Form	Result Set	Show S Numbers	Edit S Numbers					
First Hit		Previous Document		Next Document					
Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC
Help					Logout				